Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naïve patients

Journal of Infection

Volumn 58, Issue 1, 2009, Pages 61-67

  Verheyen, Jens ^a   Knops, Elena ^a   Kupfer, Bernd ^b   Hamouda, Osamah ^c   Somogyi, Sybille ^c   Schuldenzucker, Ulrike ^d   Hoffmann, Daniel ^e   Kaiser, Rolf ^a   Pfister, Herbert ^a   Kücherer, Claudia ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

^d FRESENIUS UNIVERSITY OF APPLIED SCIENCES   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Cleavage sites; Drug na ve; HIV; Mutations

Indexed keywords

GAG PROTEIN; PROTEINASE INHIBITOR;

ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA CLEAVAGE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PREVALENCE; VIRUS GENE; VIRUS STRAIN;

DRUG RESISTANCE, VIRAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV; HIV INFECTIONS; HUMANS; MUTATION, MISSENSE; POLYMORPHISM, GENETIC;

EID: 58949095759     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2008.11.009     Document Type: Article

References (28)

1. Nijhuis M., van Maarseveen N.M., Lastere S., Schipper P., Coakley E., Glass B., et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 4 1 (2007 Jan) e36
2. Doyon L., Croteau G., Thibeault D., Poulin F., Pilote L., and Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 70 6 (1996 Jun) 3763-3769
3. Zhang Y.M., Imamichi H., Imamichi T., Lane H.C., Falloon J., Vasudevachari M.B., et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 71 9 (1997 Sep) 6662-6670
4. Kolli M., Lastere S., and Schiffer C.A. Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate. Virology 347 2 (2006 Apr 10) 405-409
5. Prabu-Jeyabalan M., Nalivaika E.A., King N.M., and Schiffer C.A. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol 78 22 (2004 Nov) 12446-12454
6. Dam E, Faudon JL, Launay O, Duval X, Costagliola D, Descamps D, et al. Compensation of resistance-associated loss of replicative capacity by Gag is restricted to the NC-p1-p6 domains. Sixteenth international HIV drug resistance workshop; 2007 June 12-16, Barbados, West Indies. Antiviral Therapy.
7. De Meyer S, Azijn H, Fransen E, De Baere I, Van Ginderen M, Maes B, et al. The pathway leading to TMC114 resistance is different for TMC114 compared with other protease inhibitors. Fifteenth international HIV drug resistance workshop; 2006 June 13-17, Sitges, Spain. Antiviral Therapy.
8. Maguire M.F., Guinea R., Griffin P., Macmanus S., Elston R.C., Wolfram J., et al. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 76 15 (2002 Aug) 7398-7406
9. Prado J.G., Wrin T., Beauchaine J., Ruiz L., Petropoulos C.J., Frost S.D., et al. Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 16 7 (2002 May 3) 1009-1017
10. Ait-Khaled M, Xu F, Tisdale M, Macmanus S, Yates PJ, Elston RC, et al. Absence of protease mutations upon virological failure of first-line fosamprenavir/ritonavir is not explained by the alternative selection of p7/p1 or p1/p6 Gag cleavage site mutations. Fifteenth international HIV drug resistance workshop; 2006 June 13-17, Sitges, Spain. Antiviral Therapy.
11. Nijhuis M, Schipper P, King M, Bernstein B, Hanna G, Boucher CAB. Changes in HIV Gag and protease cannot explain persistent viraemia in the majority of patients failing first-line lopinavir/ritonavir therapy. Sixteenth international HIV drug resistance workshop; 2007 June 12-16, Barbados, West Indies. Antiviral Therapy.
12. Shafer R.W., Rhee S.Y., Pillay D., Miller V., Sandstrom P., Schapiro J.M., et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 21 2 (2007 Jan 11) 215-223
13. Verheyen J., Litau E., Sing T., Daumer M., Balduin M., Oette M., et al. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir Ther 11 7 (2006) 879-887
14. Callebaut C, Stray K, Tsai L, Xu L, Lee W, Cihlar T. In vitro HIV-1 resistance selection to GS-8374, a novel phosphonate protease inhibitor: comparison with lopinavir, atazanavir and darunavir. Sixteenth international HIV drug resistance workshop; 2007 June 12-16, Barbados, West Indies. Antiviral Therapy.
15. Garcia-Diaz A, Fox Z, Dragsted UB, Kjaer J, Clumeck N, Philips A, et al. Treatment-emergent gag cleavage site mutations during virological failure of ritonavir-boosted protease inhibitors. Seventeenth international HIV drug resistance workshop; 2008 June 10-14; Sitges, Spain. Antiviral Therapy.
16. Malet I., Roquebert B., Dalban C., Wirden M., Amellal B., Agher R., et al. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J Infect 54 4 (2007 Apr) 367-374
17. Ueda T, Myint L, Shiino T, Nishizawa M, Matsuda M, Sugiura W. Analysis of interference and co-evolution between protease inhibitor resistant mutations and gag mutations. Sixteenth international HIV drug resistance workshop; 2005 June 7-11. Quebec, Canada. Antiviral Therapy.
18. Verheyen J, Schweitzer F, Harrer E, Knops E, Müller S, Däumer M, et al. HIV p7/p1 cleavage site mutations are selected by the immune system and/or by antiretroviral therapy. Seventeenth international HIV drug resistance workshop; 2008 June 10-14, Sitges, Spain. Antiviral Therapy.
19. Oette M., Kaiser R., Daumer M., Akbari D., Fatkenheuer G., Rockstroh J.K., et al. Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany. Eur J Med Res 9 5 (2004 May 28) 273-278
20. Verheyen J, Litau E, Sing T, Schuldenzucker U, Däumer M, Oette M, et al. HIV p7/p1 and p1/p6-gag cleavage site mutations are associated with specific PR mutations and PI resistance profiles. Fifteenth international HIV drug resistance workshop; 2006 June 13-17, Sitges, Spain. Antiviral Therapy.
21. Kohli A, Parry C, Pillay D. Exploring plasma-virus-derived gag-protease interrelationships in drug resistance and fitness landscape. Sixteenth international HIV drug resistance workshop; 2007 June 12-16, Barbados, West Indies. Antiviral Therapy.
22. Nijhuis M, Wensing AM, Biermann W, de Jong D, van Rooyen WJM, Kagan R, et al. A novel genetic pathway involving L76V and M46I leading to lopinavir/r resistance. Sixteenth international HIV drug resistance workshop; 2007 June 12-16, Barbados, West Indies. Antiviral Therapy.
23. Parry CM, Kohli A, Pillay D. Gag-protease inter-relationships in drug resistance and viral fitness. Seventeenth international HIV drug resistance workshop; 2008 June 10-14, Sitges, Spain. Antiviral Therapy.
24. Quercia R, Dam E, Descamps D, Duval X, Hance A, Clavel F. Discordant effects of gag cleavage site mutations on the IC50 of protease inhibitors and on HIV replicative capacity. Boston, MA, US: CROI; 2008 February, 3-6.
25. Camacho R, Godinho AR, Gomes P, Abecasis A, Vandamme AM, Palma C, et al. Different substitutions under drug pressure at protease codon 82 in HIV-1 subtype G compared to subtype B infected individuals including a novel I82M resistance mutation. Fourteenth international HIV drug resistance workshop; 7-11 June 2005, Quebéc, Canada. Antiviral Therapy.
26. van Maarseveen NM, Schipper PJ, de Jong D, Boucher CAB, Nijhuis M. Gag NC/p1 protease resistance mutations can cause selection of additional NC/p1 changes to optimize cleavage efficiency and replicative capacity. Seventeenth international HIV drug resistance workshop; 2008 June 10-14, Sitges, Spain. Antiviral Therapy.
27. Dierynck I, De Meyer S, Cao-Van K, Van Marck H, Lathouwers E, Thys K, et al. Impact of Gag cleavage site mutations on the virological response to darunavir/ritonavir in treatment-experienced patients in POWER 1, 2 and 3. Sixteenth international HIV drug resistance workshop; 2007 June 12-16, Barbados, West Indies. Antiviral Therapy.
28. Tremblay S, Bourgon L, Hall D, Elston RC, Bethell R. Analysis of cleavage site evolution following virologic rebound on a tipranavir-based regimen. Fourth IAS conference on HIV; 2007, Sydney, Australia.